US-based genetically engineered probiotics provider ZBiotics has secured $12m in a Series A funding round led by venture capital firm Spring Tide Capital.
Access Capital, Seamless Capital, Goat Rodeo Capital, and Seaside Ventures also participated in the oversubscribed funding round.
ZBiotics intends to use the funds to meet growing consumer demand, advance retail expansion, and drive continued research and development in a new sector.
The company plans to bring new genetically engineered probiotic products to market that address the unique and newly arising biological challenges.
Spring Tide Capital co-managing partner Adam Ramada said: “Off of the breakout success of their first product, ZBiotics has more than doubled sales every year, selling over 5 million units cumulatively and reaching company-wide profitability in 2023.
“We are thrilled to support the team as they continue to expand their revolutionary probiotic platform across many more exciting use cases that address everyday consumer pain points.”
ZBiotics uses modern biotechnology to create genetically engineered probiotics for specific use cases that solve modern-day, real-world problems.
The company employs a new kind of genetic engineering technology that is transparent, responsible, and built directly for consumers.
Its lead product, Pre-Alcohol Probiotic Drink, mimics the function of the liver by breaking down acetaldehyde, the toxic byproduct of alcohol, making consumers feel better after drinking.
ZBiotics will use the funds to develop additional probiotics, using the same technology used to develop its Pre-Alcohol Probiotic Drink, for consumers looking to prioritise their health.
In addition to the Pre-Alcohol Probiotic Drink, the company plans to launch its second product in the coming weeks, which will focus on microbial diversity in the gut and associated benefits.
Furthermore, ZBiotics’ research team is actively exploring products that will address a range of health concerns such as sleep, vaginal health, and athletic performance.
ZBiotics co-founder and CEO Zack Abbott said: “Genetic engineering allows us to make totally new products that address real-world consumer needs, and we’re witnessing a growing interest in our technology and brand.
“In a market that craves real solutions, we’ve shown that being a proudly GMO company prioritizing transparency resonates with consumers, driving ZBiotics’ momentum.
“With these funds, we aim to meet demand and expand the ZBiotics product line beyond our flagship product.”
